Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8660778 | 0.81 | TK1 (0.50) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL9149865 | 0.81 | TK1 (0.50) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14827483 | 0.77 | ALDH1A1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL12416109 | 0.77 | ALDH1A1 (0.42) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL8885542 | 0.74 | ALDH1A1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL8885550 | 0.74 | ALDH1A1 (0.47) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL17236359 | 0.73 | TK1 (0.67) | TK1POLB | |
| SCHEMBL12718422 | 0.73 | TK1 (0.67) | TK1POLB | |
| SCHEMBL8885421 | 0.72 | TK1 (0.54) | TK1ALDH1A1LMNAALBPOLB | |
| SCHEMBL14827481 | 0.72 | LMNA (0.51) | TK1ALDH1A1LMNAALBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130084576-A1 | MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | RNMT, HNRNPM, NOP2 | TK1 525/4885ALDH1A1 4054/4885LMNA 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.